VKTX (STOCKS)
Viking Therapeutics, Inc
$29.500000
+0.750000 (+2.61%)
Prev close: $28.750000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Brian Lian
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,437.90M
- Employees
- 51
- P/E (TTM)
- -7.15
- P/B (TTM)
- 6.64
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
14
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.37 | $-1.03 | -0.3357 | -32.46% |
|
Dec 2025 (Q4)
|
$-1.38 | $-0.91 | -0.4680 | -51.32% |
|
Sep 2025 (Q3)
|
$-0.81 | $-0.69 | -0.1189 | -17.20% |
|
Jun 2025 (Q2)
|
$-0.58 | $-0.46 | -0.1247 | -27.39% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $393.34M |
| Research and Development | $344.96M |
| Other Operating Expenses | $48.39M |
| Operating Income/Loss | -$393.34M |
| Income/Loss From Continuing Operations After Tax | -$359.64M |
| Income/Loss From Continuing Operations Before Tax | -$359.64M |
| Income Tax Expense/Benefit | $1.00K |
| Net Income/Loss | -$359.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$359.64M |
| Net Income/Loss Available To Common Stockholders, Basic | -$359.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.19 |
| Diluted Earnings Per Share | -$3.19 |
| Basic Average Shares | 112,667,000 |
| Diluted Average Shares | 112,667,000 |
| Assets | $715.73M |
| Current Assets | $715.60M |
| Noncurrent Assets | $131.00K |
| Liabilities | $76.67M |
| Current Liabilities | $76.67M |
| Accounts Payable | $53.25M |
| Other Current Liabilities | $23.42M |
| Noncurrent Liabilities | $0.00 |
| Equity | $639.06M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $639.06M |
| Liabilities And Equity | $715.73M |
| Net Cash Flow From Operating Activities | -$278.69M |
| Net Cash Flow From Operating Activities, Continuing | -$278.69M |
| Net Cash Flow From Investing Activities | $341.39M |
| Net Cash Flow From Investing Activities, Continuing | $341.39M |
| Net Cash Flow From Financing Activities | $76.44M |
| Net Cash Flow From Financing Activities, Continuing | $76.44M |
| Net Cash Flow | $139.14M |
| Net Cash Flow, Continuing | $139.14M |
| Comprehensive Income/Loss | -$358.47M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$358.47M |
| Other Comprehensive Income/Loss | $1.17M |